129 related articles for article (PubMed ID: 19837276)
1. FGFR3 amplification in the absence of IGH@-FGFR3 fusion t(4;14) in myeloma.
Quintero-Rivera F; El-Sabbagh Badr R; Rao PN
Cancer Genet Cytogenet; 2009 Nov; 195(1):92-3. PubMed ID: 19837276
[No Abstract] [Full Text] [Related]
2. Differential nuclear organization of translocation-prone genes in nonmalignant B cells from patients with t(14;16) as compared with t(4;14) or t(11;14) myeloma.
Martin LD; Harizanova J; Righolt CH; Zhu G; Mai S; Belch AR; Pilarski LM
Genes Chromosomes Cancer; 2013 Jun; 52(6):523-37. PubMed ID: 23460268
[TBL] [Abstract][Full Text] [Related]
3. Identification of a novel IGH-MMSET fusion transcript in a human myeloma cell line with the t(4;14)(p16.3;q32) chromosomal translocation.
Intini D; Fabris S; Storlazzi T; Otsuki T; Ciceri G; Verdelli D; Lombardi L; Rocchi M; Neri A
Br J Haematol; 2004 Aug; 126(3):437-9. PubMed ID: 15257719
[No Abstract] [Full Text] [Related]
4. FGFR3 is expressed and is important for survival in INA-6, a human myeloma cell line without a t(4;14).
Våtsveen TK; Brenne AT; Dai HY; Waage A; Sundan A; Børset M
Eur J Haematol; 2009 Nov; 83(5):471-6. PubMed ID: 19594619
[TBL] [Abstract][Full Text] [Related]
5. Comparison of IGH Profile Signals Using t(4;14) and IGH Break-Apart Probes by FISH in Multiple Myeloma.
Smol T; Daudignon A
Cytogenet Genome Res; 2017; 153(1):18-21. PubMed ID: 29040969
[TBL] [Abstract][Full Text] [Related]
6. [Detection of IgH-MMSET fusion gene in multiple myeloma patients and its significance].
Jiang H; Hou J; Chen YB; Ding SQ
Zhonghua Xue Ye Xue Za Zhi; 2003 Oct; 24(10):515-8. PubMed ID: 14690579
[TBL] [Abstract][Full Text] [Related]
7. The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts.
Chesi M; Nardini E; Lim RS; Smith KD; Kuehl WM; Bergsagel PL
Blood; 1998 Nov; 92(9):3025-34. PubMed ID: 9787135
[TBL] [Abstract][Full Text] [Related]
8. A global expression-based analysis of the consequences of the t(4;14) translocation in myeloma.
Dring AM; Davies FE; Fenton JA; Roddam PL; Scott K; Gonzalez D; Rollinson S; Rawstron AC; Rees-Unwin KS; Li C; Munshi NC; Anderson KC; Morgan GJ
Clin Cancer Res; 2004 Sep; 10(17):5692-701. PubMed ID: 15355895
[TBL] [Abstract][Full Text] [Related]
9. FGFR3 preferentially colocalizes with IGH in the interphase nucleus of multiple myeloma patient B-cells when FGFR3 is located outside of CT4.
Martin LD; Harizanova J; Mai S; Belch AR; Pilarski LM
Genes Chromosomes Cancer; 2016 Dec; 55(12):962-974. PubMed ID: 27509849
[TBL] [Abstract][Full Text] [Related]
10. Ectopic expression of fibroblast growth factor receptor 3 promotes myeloma cell proliferation and prevents apoptosis.
Plowright EE; Li Z; Bergsagel PL; Chesi M; Barber DL; Branch DR; Hawley RG; Stewart AK
Blood; 2000 Feb; 95(3):992-8. PubMed ID: 10648414
[TBL] [Abstract][Full Text] [Related]
11. Chronic lymphocytic leukemia with a FGFR3 translocation: case report and literature review of an uncommon cytogenetic event.
Geller MD; Pei Y; Spurgeon SE; Durum C; Leeborg NJ
Cancer Genet; 2014; 207(7-8):340-3. PubMed ID: 25441688
[TBL] [Abstract][Full Text] [Related]
12. In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression.
Keats JJ; Reiman T; Maxwell CA; Taylor BJ; Larratt LM; Mant MJ; Belch AR; Pilarski LM
Blood; 2003 Feb; 101(4):1520-9. PubMed ID: 12393535
[TBL] [Abstract][Full Text] [Related]
13. Detection and follow-up of fibroblast growth factor receptor 3 expression on bone marrow and circulating plasma cells by flow cytometry in patients with t(4;14) multiple myeloma.
Chandesris MO; Soulier J; Labaume S; Crinquette A; Repellini L; Chemin K; Malphettes M; Fieschi C; Asli B; Uzunhan Y; Fermand JP; Bories JC; Arnulf B
Br J Haematol; 2007 Feb; 136(4):609-14. PubMed ID: 17223917
[TBL] [Abstract][Full Text] [Related]
14. A subset of multiple myeloma harboring the t(4;14)(p16;q32) translocation lacks FGFR3 expression but maintains an IGH/MMSET fusion transcript.
Santra M; Zhan F; Tian E; Barlogie B; Shaughnessy J
Blood; 2003 Mar; 101(6):2374-6. PubMed ID: 12433679
[TBL] [Abstract][Full Text] [Related]
15. Detection of t(4;14)(p16.3;q32) chromosomal translocation in multiple myeloma by double-color fluorescent in situ hybridization.
Finelli P; Fabris S; Zagano S; Baldini L; Intini D; Nobili L; Lombardi L; Maiolo AT; Neri A
Blood; 1999 Jul; 94(2):724-32. PubMed ID: 10397739
[TBL] [Abstract][Full Text] [Related]
16. Interphase detection of t(4;14)(p16.3;q32.3) by in situ hybridization and FGFR3 overexpression in plasma cell malignancies.
Nakazawa N; Nishida K; Tamura A; Kobayashi M; Iwai T; Horiike S; Nishigaki H; Otsuki T; Tomiyama Y; Fujii H; Kashima K; Taniwaki M
Cancer Genet Cytogenet; 2000 Mar; 117(2):89-96. PubMed ID: 10704676
[TBL] [Abstract][Full Text] [Related]
17. Double-hit myeloma with IGH/MYC and IGH/CCND1 translocations.
Ji M; Jang S; Lee JH; Seo EJ
Ann Hematol; 2013 Aug; 92(8):1129-31. PubMed ID: 23307601
[No Abstract] [Full Text] [Related]
18. Detection of t(4;14)(p16.3;q32) chromosomal translocation in multiple myeloma by reverse transcription-polymerase chain reaction analysis of IGH-MMSET fusion transcripts.
Malgeri U; Baldini L; Perfetti V; Fabris S; Vignarelli MC; Colombo G; Lotti V; Compasso S; Bogni S; Lombardi L; Maiolo AT; Neri A
Cancer Res; 2000 Aug; 60(15):4058-61. PubMed ID: 10945609
[TBL] [Abstract][Full Text] [Related]
19. Deregulated FGFR3 mutants in multiple myeloma cell lines with t(4;14): comparative analysis of Y373C, K650E and the novel G384D mutations.
Ronchetti D; Greco A; Compasso S; Colombo G; Dell'Era P; Otsuki T; Lombardi L; Neri A
Oncogene; 2001 Jun; 20(27):3553-62. PubMed ID: 11429702
[TBL] [Abstract][Full Text] [Related]
20. A molecular study of the t(4;14) in multiple myeloma.
Sibley K; Fenton JA; Dring AM; Ashcroft AJ; Rawstron AC; Morgan GJ
Br J Haematol; 2002 Aug; 118(2):514-20. PubMed ID: 12139740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
